Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement

①Tonight, lepu medical technology announced that General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned, and the Chairman's daughter Pu Fei took over as General Manager, with a "sea turtle elite" background; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, and the market cap has dropped by one quarter compared to its peak period.

cls.cnSep 25 11:34 ET

Contec Medical Systems: Will increase layout efforts in Africa, and multiple in-vitro diagnostic products are expected to be registered within the year.|Focus on the earnings conference

① The decline in performance in the first half of the year is attributed to a reduction in orders due to downstream customers destocking and a high base from the previous year; ② Currently, bulk production of zirconia ceramic blocks for all-ceramic dentures has been achieved, and multiple ex vivo diagnostic products have entered the late stage of development, with registration expected to be completed within the year; ③ The company has made market breakthroughs in several countries in Africa and will continue to focus on the African market, increasing product distribution and marketing efforts.

cls.cnSep 12 10:33 ET

Is it difficult to do business both online and offline? Shanghai Rongtai Health Technology Corporation: Product prices continue to decline, the halo of top hosts is no longer shining | Interpretations

①After experiencing two consecutive years of declining revenue, the domestic massage chair leader Shanghai Rongtai Health Technology Corporation saw a further decline in revenue in the first half of the year; ②Against the backdrop of weak market demand and intensified competition, the company's offline business product prices continued to decrease; ③In terms of online business, the company stated that the influence of top KOLs weakened, platform price wars and subsidy policies were frequent, algorithmic price comparisons intensified, and gross margins decreased across various channels.

cls.cnAug 27 12:03 ET

Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations

①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.

cls.cnAug 23 08:58 ET

AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.

Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.

wallstreetcnJul 1 22:02 ET

2024 Financial Report | After the dividend ratio is close to 100%, Donga Ejiao still has 8 billion

Extravagant dividends

wallstreetcnMar 22 04:25 ET